AMEX
ASX
CPH
DOH
EURONEXT
HEL
HKSE
JKT
JPX
LSE
MEX
NSE
OSE
SHH
SIX
STO
TSX
XETRA
Russian
Lithuanian@ NOK2.02
Issued: 24 Mar 2023 @ 08:28
Return: 1.74%
Previous signal: Mar 17 - 09:57
Previous signal:
Return: 2.81 %
Live Chart Being Loaded With Signals
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform...
| Stats | |
|---|---|
| Current Price | NOK2.05 |
| Today's Volume | 36 185T |
| Average Volume | 500 465T |
| Market Cap | 76.52M |
| EPS | NOK 0 |
| P/E | 0 |
| ATR14 | NOK 0.0400 (1.95%) |
PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.